The European Pharmacopoeia Commission added 19 new monographs and three new chapters and revised 51 monographs and 15 chapters.
The European Pharmacopoeia Commission
announcedon April 5, 2018 that it had adopted 19 new monographs and three new chapters to the European Pharmacopoeia (Ph. Eur.). Additionally, during the 160th session of the commission, 51 monographs and 15 chapters were revised. The new and revised texts will be effective April 1, 2019 and will be published in Supplement 9.7 of the Ph. Eur.
The following are included in the Ph. Eur. updates:
Also decided by the commission at the session was reactivation of its Working Party on Gene Therapy products in view of recent developments in the field; reengagement of work on a general chapter on a test for bacterial endotoxins using recombinant Factor C, avoiding the use of a reagent coming from endangered species (horseshoe crab); and addition of 18 new texts to its work program, including four new general chapters [on congealing point determination (2.2.68), multivariate statistical process control (5.28), test for bacterial endotoxins using recombinant factor C (2.6.32) and Recommendations on testing of particulate contamination-visible particles (5.17.2)].
Source:
EDQM
A Novel, Enhanced, and Sustainable Approach to Audit Trail Review
July 4th 2025Eli Lilly and Company developed an innovative and sustainable approach to audit trail review (ATR) aimed at reducing the ATR burden while adhering to regulatory expectations and data integrity (DI) principles. The process has transformed employees' understanding of ATR and complemented the DI by design approach, leading to better system designs that meet expected controls and reduce non-value-added data reviews.